Literature DB >> 10981209

Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life.

A M Damiano1, M M McGrath, M K Willian, C F Snyder, P A LeWitt, P F Reyes, R R Richter, E D Means.   

Abstract

This study evaluated the feasibility and psychometric properties of self-completed and telephone interview versions of a patient health-related quality-of-life (HQL) questionnaire for Parkinson's disease that included the SF-36 Health Survey (SF-36), the Parkinson's Disease Questionnaire (PDQ-39), and the Medical Outcomes Study Sexual Function Survey. Parkinson's disease patients (n = 150) completed the questionnaire twice: once at the study site and once over the telephone in a randomized order. Ninety-four percent of enrolled patients completed the first HQL assessment and 88% completed both assessments. Cronbach's alpha exceeded 0.70 for all scales except for the self-completed PDQ-39 Social Support subscale (0.57) and the telephone interview PDQ-39 Social Support (0.60) and Cognitions (0.67) subscales and the SF-36 General Health (0.60) and Social Function (0.61) subscales. There were no statistically significant differences in mean HQL scale scores across the two modes of administration. Mean scores for 3 of the PDQ-39 subscales and the Summary Index were significantly poorer (p < 0.05) for patients at later clinical stages. Similarly, patients with dyskinesias reported significantly poorer scores for 4 of the PDQ-39 subscales and the Summary Index and patients with self-reported comorbidities reported poorer SF-36 Physical Function and General Health subscale scores than patients without dyskinesias and comorbidities, respectively. This study suggests that the self-completed and telephone interview versions of the patient HQL questionnaire are feasible and valid for future clinical trial applications.

Entities:  

Mesh:

Year:  2000        PMID: 10981209     DOI: 10.1023/a:1008928321652

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  18 in total

1.  A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease.

Authors:  M Sano; Y Stern; K Marder; R Mayeux
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

2.  Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group.

Authors:  F Grandas; P Martínez-Martín; G Linazasoro
Journal:  J Neurol       Date:  1998-05       Impact factor: 4.849

3.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

Authors:  G Block; C Liss; S Reines; J Irr; D Nibbelink
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

4.  Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Authors:  H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

5.  Comparisons of the costs and quality of norms for the SF-36 health survey collected by mail versus telephone interview: results from a national survey.

Authors:  C A McHorney; M Kosinski; J E Ware
Journal:  Med Care       Date:  1994-06       Impact factor: 2.983

6.  Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)

Authors:  C Jenkinson; V Peto; R Fitzpatrick; R Greenhall; N Hyman
Journal:  Age Ageing       Date:  1995-11       Impact factor: 10.668

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.

Authors:  R Pahwa; K Lyons; D McGuire; P Silverstein; F Zwiebel; M Robischon; W C Koller
Journal:  Mov Disord       Date:  1997-09       Impact factor: 10.338

9.  Quality of life in patients with Parkinson's disease: development of a questionnaire.

Authors:  A G de Boer; W Wijker; J D Speelman; J C de Haes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

10.  Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders.

Authors:  R Fitzpatrick; V Peto; C Jenkinson; R Greenhall; N Hyman
Journal:  Mov Disord       Date:  1997-11       Impact factor: 10.338

View more
  34 in total

1.  Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments.

Authors:  J Marinus; C Ramaker; J J van Hilten; A M Stiggelbout
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  The relative health related quality of life of veterans with Parkinson's disease.

Authors:  H Gage; A Hendricks; S Zhang; L Kazis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

4.  Functional limitations and well-being in injured municipal workers: a longitudinal study.

Authors:  Marion Gillen; Sarah A Jewell; Julia A Faucett; Edward Yelin
Journal:  J Occup Rehabil       Date:  2004-06

Review 5.  [Deep brain stimulation for Parkinson's disease].

Authors:  J Herzog; G Deuschl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 6.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

7.  Minority enrollment in Parkinson's disease clinical trials.

Authors:  Myra G Schneider; Christopher J Swearingen; Lisa M Shulman; Jian Ye; Mona Baumgarten; Barbara C Tilley
Journal:  Parkinsonism Relat Disord       Date:  2008-08-09       Impact factor: 4.891

8.  Parkinson's disease: how is employment affected?

Authors:  R Murphy; N Tubridy; H Kevelighan; S O'Riordan
Journal:  Ir J Med Sci       Date:  2013-01-17       Impact factor: 1.568

Review 9.  The effect of deep brain stimulation on quality of life in movement disorders.

Authors:  A Diamond; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

10.  Testing the SF-36 in Parkinson's disease. Implications for reporting rating scale data.

Authors:  P Hagell; A L Törnqvist; J Hobart
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.